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Background: The present study examines the presentation and outcomes of hepatocellular carcinoma
(HCC) at a Western centre over the last decade.
Methods: Between January 2000 and September 2009, 1010 patients with HCC were evaluated at the
University of Pittsburgh Medical Center (UPMC). Retrospectively, four treatment groups were classified:
no treatment (NT), systemic therapy (ST), hepatic artery-based therapy (HAT) and surgical intervention (SI)
including radiofrequency ablation, hepatic resection and transplantation. Kaplan–Meier analysis assessed
survival between groups. Cox regression analysis identified factors predicting survival.
Results: Patients evaluated were 75% male, 87% Caucasian, 84% cirrhotic, and predominantly diag-
nosed with hepatitis C. In all, 169 patients (16.5%) received NT, 25 (2.4%) received ST, 529 (51.6%)
received HAT and 302 (29.5%) received SI. Median survival was 3.6, 5.6, 8.8, and 83.5 months with NT,
ST, HAT and SI, respectively (P = 0.001). Transplantation increased from 9.5% to 14.2% after the model
for end-stage liver disease (MELD) criteria granted HCC patients priority points. Survival was unaffected
by bridging transplantation with HAT or SI (P = 0.111). On multivariate analysis, treatment modality was
a robust predictor of survival after adjusting for age, gender, AFP, Child–Pugh classification and cirrhosis
(P < 0.001, c2 = 460).
Discussion: Most patients were not surgical candidates and received HAT alone. Surgical intervention,
especially transplantation, yields the best survival.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common solid
malignancy worldwide, with more than 1 million new diagnoses
made each year. Prognosis remains extremely poor with more
than 600 000 deaths occurring annually, and a 5-year survival rate
of less than 5% without treatment.1,2 In the United States, the
current steady rise in incidence is largely as a result of hepatitis C
(HCV).3 While recognized risk factors include viral hepatitis,
hereditary haemochromatosis and environmental toxins, hepatitis
B (HBV) and HCV are the predominant causes of HCC world-
wide. Cirrhosis is present in 50–80% of patients who develop
HCC.4–6
Surgical resection and liver transplantation are still the primary
curative options for HCC. Liver transplantation offers a potential
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cure for the disease and also addresses underlying cirrhosis, which
itself can behave as a premalignant condition.7–10 The role of liver
transplantation has evolved over time.An important modification
was the adaptation by the United Network for Organ Sharing
(UNOS) of the United States to provide priority to HCC patients
listed for liver transplantation who present with early-stage HCC
under the Milan criteria.7,9–12
However, less than 20% of patients are deemed eligible for
curative resection in the United States and few patients actually
receive a liver transplantation as a result of limited organ
availability.13–15 Over the past two decades, major advances in the
understanding of HCC tumour biology have led to new therapeu-
tic options, significantly altering clinical management. Beyond the
minority of patients who are candidates for curative surgical inter-
vention, a multimodal management approach for non-surgical
candidates provides a greater focus on slowing or even reversing
tumour progression. The primary goal is to extend survival for
non-surgical candidates for possible curative surgery or liver
transplantation. Directed hepatic arterial-based loco-regional
therapy, including bland embolization, transcatheter arterial
chemoembolization (TACE) and yttium90 microsphere radioem-
bolization (Y90), utilizes differential hepatic artery blood supply
for tumour growth.16–21 Several studies have shown promising
results with loco-regional transarterial-based treatment, including
tumour necrosis and a delay in tumour progression and vascular
invasion.16 Hepatic transarterial treatment is also utilized to
downstage patients who exceed the Milan transplant criteria and
to bridge patients awaiting transplantation.8,22–25 Local ablative
treatment has also emerged as an important therapeutic option,
especially in the cirrhotic liver. Ablative techniques cause cellular
damage and achieve therapeutic effect by modifying temperature
(radiofrequency ablation,microwave ablation, or cryoablation) or
by direct exposure to toxic substances (ethanol or acetic acid
injection). Studies have demonstrated similar overall survival
rates for ablative treatment and liver resection.26–33 Systemic treat-
ment options for unresectable HCC are limited. Sorafenib, a
multi-kinase inhibitor, was approved by the US Food and Drug
Administration in 2007.34 The Sorafenib HCC Assessment Ran-
domized Protocol (SHARP) trial shows it is the first systemic
chemotherapeutic agent that has been shown to improve
survival.34–36
While many large series report the management of HCC, most
are from Asian countries where HCC is endemic.37–43 The purpose
of the present study was to describe the presentation, manage-
ment and outcome of patients with HCC who are managed at a
single large Western tertiary care centre.
Methods
Between January 2000 and September 2009, 1010 patients diag-
nosed with HCC were evaluated at the University of Pittsburgh
Medical Center (UPMC) Liver Cancer Center (LCC) in Pitts-
burgh, PA, USA. Data were analysed retrospectively from a pro-
spective Institutional Review Board-approved hepatic cancer
registry. Factors examined included demographics (age, gender
and race), presence of cirrhosis, aetiology of hepatitis, Child–Pugh
classification, clinical laboratory values, treatment modality and
survival outcome.
Diagnosis of HCC was made during initial evaluation or before
referral to the LCC. Evaluation included clinical laboratory values
(complete blood count, basic metabolic panel, coagulation studies
and liver function tests), hepatitis screening, analysis for tumour
markers [alpha-fetoprotein (AFP), CEA and CA19-9] and radio-
graphical studies including a triphasic helical computed axial
tomography (CT) scan andmagnetic resonance imaging (MRI).A
liver biopsy was performed when a diagnosis could not be deter-
mined based on laboratory (AFP 400 ng/mL) and radiographi-
cal data alone. Diagnosis and treatment recommendations were
made for all patients at a weekly multidisciplinary liver tumour
conference.44
Patients were categorized into four main treatment groups: no
treatment (NT), systemic therapy (ST), hepatic artery-based
therapy (HAT) and surgical intervention (SI). The NT group
included patients who received best supportive care only. The ST
group included patients who received oral systemic sorafenib
treatment. The HAT group included patients who received bland
embolization, TACE or Y90 treatment alone. The SI group
included patients who underwent RFA, hepatic resection or liver
transplantation. TACE,Y90 and RFA were performed as described
previously.22,45,46
As a result of the complexity of analysing multimodal
management, patients who ever received surgical therapy
were classified in the SI group regardless of prior or subsequent
HAT therapy. Within the SI group, patients were classified
under the RFA treatment group regardless of prior HAT,
hepatic resection group regardless of prior HAT or RFA, and
liver transplantation group regardless of any type of prior
therapy.
Comparisons were also made between two time periods:
before the model for end-stage liver disease (MELD) criteria
change in March 2003 and after the MELD criteria change which
granted priority points to patients with HCC. The two eras were
defined as the pre-current MELD era (January 2000 until March
2003) and the current MELD era (March 2003 until September
2009).
Data analysis was performed using PASW Statistics 18 for
Windows (version 18.0; SPSS Inc., Chicago, IL, USA). Groups
were compared using the c2 test for independence for categorical
variables. Analysis of variance was used for normally distributed
continuous variables, and the Mann–Whitney U- and Kruskal–
Wallis tests were employed for non-normally distributed continu-
ous variables. Overall survival was the primary endpoint of the
study. Duration of survival was calculated from the time of evalu-
ation at the LLC to death or loss to follow-up. Actuarial survival
was calculated using Life Tables. The Kaplan–Meier method was
used to compare survival between groups. Cox regression analysis
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was used to test predictors of survival.Variables that were found to
significantly predict survival were included in a multivariate Cox
regression model.
Results
Between January 2000 and September 2009, 1010 patients diag-
nosed with HCC were managed at the UPMC LCC whose treat-
ments are summarized in Fig. 1. In all, 639 (63.3%) patients had
HAT with or without subsequent therapy, 448 (44.4%) received
TACE and 174 (17.2%) received Y90 with or without subsequent
therapy, 529 patients received HAT alone; 20 (2.0%), 371 (36.7%)
and 138 (13.7%) patients received bland embolization, TACE and
Y90 alone, respectively. Subgroup analysis of the SI group shows
that 12 (22.6%) patients with RFA received additional HAT before
or after ablation (eight patients received TACE and four received
Y90).Analysis of patients with a liver resection showed 27 (22.0%)
received additional HAT before or after surgery (17 patients
received TACE and 10 received Y90). Patients with liver transplan-
tation received the most additional therapy; only 31 (24.6%)
received a transplant alone, 52 (41.3%) transplanted patients had
prior TACE, 19 (15.1%) had prior Y90, 19 (15.1%) had prior RFA
and 5 (4.0%) had a prior resection and 7 (5.6%) patients received
both SI and HAT before transplantation. Overall, 121 (12.0%)
patients had multimodal therapies, of which 75 were bridged
transplants.
Patient demographics, presence of cirrhosis, etiology of hepa-
titis and Child–Pugh classification is presented for all patients and
by treatment group in Table 1. Data were available for age, gender,
cirrhosis, hepatitis, Child–Pugh classification, and ethnicity for
1010 (100%), 1007 (99.7%), 923 (91.4%), 901 (89.2%), 989
(97.9%), and 996 (98.6%) patients, respectively, and all percent-
ages shown in Table 1 refer to available data only. Patients with ‘no
viral hepatitis’ had a negative screen for HBV and HCV. It is
unclear whether this is underestimated as a result of missing data
for hepatitis screening in 109 (10.8%) patients. There are also
more patients with Child–Pugh classifications than cirrhotic
patients because of a lack of recorded cirrhosis data for 87 (8.6%)
patients. Most patients were Caucasian males with underlying
viral hepatitis and cirrhosis, and were not candidates for surgical
treatment. HAT and SI tended to be offered to more Child–Pugh
class A patients and those without underlying cirrhosis, whereas
NT and ST was offered to more Child–Pugh class B and C patients
with underlying cirrhosis.
Clinical laboratory values at initial evaluation were analysed.
Median bilirubin, albumin, prothrombin time (PT), international
normalized ratio (INR), blood urea nitrogen (BUN), creatinine
and platelets were within normal limits. However, median aspar-
tate transaminase (AST), alanine transaminase (ALT), alkaline
phosphatase (ALP) and AFP were increased. Median AST was
65 U/L with an interquartile range (IQR) of 75 U/L; median
alanine transaminase (ALT) was 51 (IQR 44) U/L; median alkaline
phosphatase (ALP) was 145.5 (124) U/L; median AFP was 51
(1301) ng/mL. Considering patients with available AFP data, 346
(40.0%) had a normal AFP (<20 ng/mL), 228 (26.4%) had an AFP
 20 ng/mL but <400 ng/mL and 291 (33.6%) had an AFP 
400 ng/mL.Median AFP was significantly different between treat-
ment groups using the Mann–Whitney U-test (P < 0.001), with
the SI group having the lowest median AFP of 13 (165.5) ng/mL.
Comparisons were made before and after the MELD criteria
changed in March 2003 to grant priority points to patients with
HCC.47 Patient characteristics and treatments received over these
time periods are shown in Table 2 and Table 3, respectively.
Median 1-, 3- and 5-year survival based on treatment modality
is shown in Table 4, with Kaplan–Meier analysis shown in Fig. 2.
The SI group was broken down into subgroups of radiofrequency
ablation (RFA), resection and transplantation; survival is summa-
rized in Table 5 and Fig. 3.
Survival based on the bridging therapy to transplant is summa-
rized in Fig. 4. The mean survival was 7.6 years for transplanted
patients with a prior RFA or resection (n = 64), 7.4 years for
transplanted patientswith prior TACEorY90 (n= 24) and 6.1 years
for patients transplanted with no prior bridging therapy (n = 31),
but these differences in survival were not significant (P = 0.111).
Patients were compared using Child–Pugh class at presentation
to assess the impact of severity of cirrhosis on survival. Median
survival was 16.6 months for patients with Child–Pugh class A
(n = 645) versus 6.6 months for patients with Child–Pugh classes
B or C (n = 344) (P < 0.001), shown in Fig. 5. Child–Pugh class
similarly determined survival within treatment groups. For NT
patients, median survival was 4.6 months for class A (n = 44) and
2.0 months for classes B or C (n = 94) (P < 0.01). For HAT
52%
15%
30%
12%
13%
5%
3%
RFASIHAT
ST NT
Resection
Transplantation
Figure 1 Breakdown of treatment modalities for hepatocellular carcinoma patients. NT, no treatment; ST, systemic therapy; HAT, hepatic
artery-based therapy; SI, surgical intervention; RFA, radiofrequency ablation
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patients, median survival was 11.2 months for class A (n = 388)
and 5.2 months for classes B or C (n = 139) (P < 0.001). For SI
patients, median survival was 100.3 months for class A (n = 207)
and 41.4 months for classes B or C (n = 97) (P = 0.01).
The prognostic value of AFP was assessed using a 400 ng/mL
cutoff. Median survival was 20.0 months for all patients with an
AFP level below the cutoff (<400 ng/mL) (n = 574) and only 5.8
months for all patients above the cutoff (400 ng/mL) (n = 291)
Table 1 Clinical characteristics of all patients and by treatment modality
NT ST HAT SI P-value Alla
Number of patients 154 (15.2%) 25 (2.5%) 529 (52.4%) 302 (29.9%) 1010
Age (years  SD) 63  12 61  13 64  13 60  14 <0.01 62  13
Male (%) 125 (81.2%) 21 (84.0%) 403 (76.2%) 209 (69.9%) 0.03 758 (75.3%)
Cirrhosis (%) 129 (92.8%) 22 (100%) 393 (81.7%) 229 (81.5%) <0.01 773 (83.7%)
Hepatitis <0.001
B only (%) 8 (6.0%) 1 (6.3%) 42 (8.5%) 30 (11.7%) 81 (9.0%)
C only (%) 51 (38.1%) 10 (62.5%) 119 (24.0%) 97 (37.9%) 277 (30.7%)
B & C (%) 19 (14.2%) 0 (0%) 56 (11.3%) 32 (12.5%) 107 (11.9%)
No viral hepatitis (%)b 56 (41.8%) 5 (31.3%) 278 (56.2%) 97 (37.9%) 436 (48.4%)
Child–Pugh <0.001
A (%) 44 (31.9%) 6 (27.3%) 388 (73.6%) 207 (68.5%) 645 (65.2%)
B (%) 78 (56.5%) 13 (59.1%) 135 (25.6%) 80 (26.5%) 306 (30.9%)
C (%) 16 (11.6%) 3 (13.6%) 4 (0.8%) 15 (5.0%) 38 (3.8%)
Ethnicity 0.861
Caucasian (%) 127 (86.4%) 21 (84.0%) 463 (88.2%) 259 (86.6%) 870 (87.3%)
African American (%) 15 (10.2%) 3 (12.0%) 43 (8.2%) 26 (8.7%) 87 (8.7%)
Asian (%) 1 (0.7%) 1 (4.0%) 11 (2.1%) 8 (2.7%) 21 (2.1%)
Other (%) 4 (2.7%) 0 (0%) 8 (1.5%) 6 (2.0%) 18 (1.8%)
aPercentages presented are only for patients with available data.
bPatients with a negative screen for HBV and HCV.
NT, no treatment; ST, systemic therapy; HAT, hepatic artery-based therapy; SI, surgical intervention.
Table 2 Clinical characteristics by pre-current model for end-stage liver disease (MELD) (until 03/03) and current MELD eras
Pre-current MELD Era Current MELD Era P-value
Number of Patients 293 717
Age (years) 62  15 63  12 0.883
Male (%) 220 (75.1%) 538 (75.4%) 0.930
Cirrhosis (%) 218 (77.3%) 555 (86.6%) <0.001
Hepatitis 0.01
B only (%) 26 (9.4%) 55 (8.8%)
C only (%) 73 (26.3%) 204 (32.7%)
B & C (%) 24 (8.6%) 83 (13.3%)
No hepatitis (%) 155 (55.8%) 281 (45.1%)
Child–Pugh 0.889
A (%) 191 (66.1%) 454 (64.9%)
B (%) 88 (30.4%) 218 (31.1%)
C (%) 10 (3.5%) 28 (4.0%)
Ethnicity 0.373
Caucasian (%) 254 (87.6%) 616 (87.3%)
African American (%) 21 (7.2%) 66 (9.3%)
Asian (%) 9 (3.1%) 12 (1.7%)
Other (%) 6 (2.1%) 12 (1.7%)
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(P < 0.001), shown in Fig. 6. This trend was the same within
treatment groups. For NT patients, median survival was 3.6
months when AFP was below the cutoff (n = 56) and 1.6 months
when AFP was above the cutoff (n = 29) (P < 0.01). For HAT
patients, median survival was 14.9 months when AFP was below
the cutoff (n = 289) and 4.8 months when AFP was above the
cutoff (n = 203) (P < 0.001). For SI patients, there was a longer
survival of 100.3 months whenAFP was below the cutoff (n = 220)
versus 34.2 months when AFP was above the cutoff (n = 53), but
this was not significant (P = 0.107).
Analysis was performed for patients with viral hepatitis.
Patients with HBV (n = 81) had a median survival of 12.0
months [95% confidence interval (CI) 6.5–17.5 months] which
was not significantly different (P = 0.640) compared with
patients with HCV, concomitant HBV and HCV, and no under-
lying hepatitis [survival of 10.3 (6.8–13.8), 10.5 (4.4–16.7), 13.2
(10.6–15.8) months and n = 277, 107, 436, respectively].
However, hepatitis type was significant when only considering
patients who received a liver resection; median survival was 41.9
months for the patients with HBV (n = 13) versus 22.4 months
for the patients with HCV (n = 25) (P < 0.05). The presence of
cirrhosis differed between these resection groups: 9 (69%)
patients with HBV had cirrhosis whereas all 25 (100%) patients
with HCV had cirrhosis.
Univariate analysis for prognostic factors found age (P = 0.041),
gender (P < 0.001), AFP  400 ng/mL (P < 0.001), Child–Pugh
classification (P < 0.001), cirrhosis (P = 0.002) and treatment
modality (P < 0.001) to be significant predictors of survival.
Multivariate analysis shows treatment modality to be a robust
Table 3 Treatment trends based pre-current model for end-stage liver disease (MELD) (until 03/03) and current MELD eras
Pre-current MELD era Current MELD era P-value
NT 50 (17.1%) 104 (14.5%) 0.304
ST 0 (0%) 25 (3.5%) <0.01
HAT 201 (68.6%) 328 (45.7%) <0.001
SI 42 (14.3%) 260 (36.3%) <0.001
SI subgroups
RFA 9 (3.1%) 44 (6.1%) <0.05
Resection 10 (3.4%) 113 (15.8%) <0.001
Transplant 23 (7.8%) 103 (14.2%) <0.01
NT, no treatment; ST, systemic therapy; HAT, hepatic artery-based therapy; SI, surgical intervention; RFA, radiofrequency ablation.
Table 4 Actuarial survival based on treatment modality
1 year (%) 3 years (%) 5 years (%) Median survival (months, 95% CI)a
NT 17 5 0 2.8 (1.9–3.8)
ST 23 0 0 5.6 (2.5–8.6)b
HAT 42 12 6 8.8 (7.5–10.1)c
SI 85 63 54 83.5 (51.6–115.4)c
CI, confidence interval; NT, no treatment; ST, systemic therapy; HAT, hepatic artery-based therapy; SI, surgical intervention.
aMedian survival determined using the Kaplan–Meier method.
bNo significant difference in survival compared to no treatment (P = 0.309).
cSignificant difference in survival compared to no treatment (P < 0.001).
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Figure 2 Survival by treatment modality. NT, no treatment; ST,
systemic therapy; HAT, hepatic artery-based therapy; SI, surgical
intervention
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predictor of survival (P < 0.001, c2 = 460) after adjusting for
significant predictors of survival by univariate analysis (Table 6).
Discussion
HCC is a common cause of cancer-related death worldwide, with
a steadily increasing incidence in the United States.3 The manage-
ment of HCC has evolved over the past two decades along with a
better understanding of HCC tumour biology and advancements
in therapeutic modalities. Nevertheless, the management of HCC
varies widely depending on the extent of disease, level of hepatic
functional reserve and overall functional status of patients. While
the need exists for an integrated comprehensive treatment
approach, HCC is a complex disease with constantly changing
management. There is also no universal system for staging HCC.
The Barcelona Clinic Liver Center (BCLC) staging system has
gained widespread acceptance over TNM classification as it goes
beyond pathological staging to incorporate functional liver status
and cancer-related symptoms.23,48,49 Most large published series
describing presentation and treatment of HCC are from Asian
centres, which account for more than 75% of the new HCC diag-
noses made globally each year.37–43,50 In Asia, there is a variety of
underlying liver diseases, with HBV as the main aetiological fac-
tor.42 This is in contrast to the United States, where HCV is the
predominant cause of HCC. In most Asia-Pacific countries,
chronic HBV infection is the cause for 75–80% of HCC; Japan,
Singapore, Australia and New Zealand are exceptions with a
higher prevalence of HCV infection.51 Similar to the United States,
the management of HCC has a multimodal approach, with the
utilization of loco-regional treatment such as TACE and Y90 in
downstaging or bridging non-resectable patients to salvage liver
surgery or transplantation.31,40,52
Table 5 Actuarial survival based on treatment modality (SI group)
1 year (%) 3 years (%) 5 years (%) Median survival (months, 95% CI)a
RFA (n = 53) 86 47 36 31.6 (20.1–43.1)b
Resection (n = 123) 81 57 47 44.5b,c
Transplant (n = 126) 89 73 66 100.3b
CI, confidence interval; RFA, radiofrequency ablation.
aMedian survival determined using the Kaplan–Meier method.
bSignificant difference in survival compared with no treatment (P < 0.001).
cNo significant difference in survival compared with RFA (P = 0.404).
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Figure 3 Survival by surgical intervention. RFA, radiofrequency
ablation
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This study is significant as it describes the presentation, man-
agement and outcomes of patients with HCC at a large Western
Center.Most patients evaluated were Caucasianmales with under-
lying cirrhosis and viral hepatitis. Comparing the first 3 and last 6
years of the study, HCV incidence increased from 34.9% to 45%
(P < 0.001), consistent with the national trends.3 More patients
had underlying cirrhosis over these subsequent time periods
(77.3% to 86.6%, P < 0.01).
Multivariate analysis found treatment modality to be a robust
predictor of survival after adjusting for other significant factors.
Less than one-third of patients were managed with SI; liver resec-
tion and transplantation were treatments for 12.1% and 12.5% of
patients, respectively. It is well recognized that liver resection and
liver transplantation are the primary curative therapeutic options
for HCC, yielding a 5-year survival of 60–70% in well-selected
patients.7 However, as the BCLC staging system attempted to
address, most patients are not candidates for liver resection as a
result of extensive disease at presentation, diminished underlying
liver function and poor patient performance status.23,48,49 In the
present study, most patients receiving SI (68.5%) were Child–
Pugh class A whereas only 5% were Child–Pugh class C. This
illustrates the selection bias when considering SI as a treatment.
Interestingly, SI increased significantly between the two study
periods from 14.3% to 36.3% (P < 0.001). This increase is likely
multifactorial. Outreach programmes and education for primary
care and community physicians led to improved surveillance and
detection of high-risk patients, resulting in increased early refer-
ring patterns to our tertiary care centre.44 Liver transplantation
was a more frequent treatment (7.8% to 14.2%, P < 0.01) for
patients with HCC when the new MELD scoring system granted
bonus points to patients with stage II HCC and liver cirrhosis. The
increase in liver resections (3.4% to 15.8%, P < 0.001) had the
largest impact on the overall increase in SI. Resection criteria were
generally broadened because of several factors: improvements in
surgical techniques with new coagulation devices, a better under-
standing of intricate liver anatomy, enhanced management of
hepatic cirrhosis, improved anaesthetic care and an integrated
post-operative care approach. It is interesting and unexpected that
the overall frequencies of resection and transplantation were
similar. However, comparing between the two MELD eras, the
increase in liver resection exceeds that of transplantation. At this
point, it is difficult to predict if the frequency of liver resection will
continue to increase and surpass liver transplantation. With
limited organ availability and advancements in peri-operative
care, it is likely that liver resection will be a leading curative
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Figure 5 Survival by Child–Pugh classification
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Figure 6 Survival by alpha-fetoprotein (AFP) level (400 ng/mL cutoff)
Table 6 Clinical predictors of survival based on multivariate analysis
Predictor Hazard ratio 95% CI P-value
Age 1.004 {0.997–1.0} 0.320
Gender 1.325 {1.071–1.640} <0.01
Child–Pugh (A vs. B/C) 0.584 {0.487–0.700} <0.001
AFP (<400 vs. 400) 0.427 {0.358–0.509} <0.001
Cirrhosis 1.127 {0.881–1.440} 0.342
Treatment modalitya 0.598 {0.560–0.638} <0.001
aSix treatments were compared (the SI group was subdivided to RFA,
resection and transplantation).
CI, confidence interval; AFP, alpha-fetoprotein.
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option. The doubling in rate of RFA over the two study periods
(3.1% to 6.1%, P < 0.05) is as a result of its two unique and
growing applications. RFA was utilized to treat non-surgical can-
didates with early stage HCC and poor underlying liver functional
reserve or difficult-to-resect tumour location. It was also used as
bridging therapy for patients who were awaiting transplantation.44
Our experience showed that 17.9% of transplanted patients were
bridged with RFA, compared with 4.7% bridged with liver resec-
tion. There appears to be improved survival with liver resection
alone compared with RFA alone (44.5 versus 31.6 months) but
this difference was not statistically significant (P = 0.404). Several
studies have similarly described bridging to transplant with RFA
and demonstrated comparable survival benefits of using RFA and
liver resection for HCC < 3 cm in diameter.22,33,53
Mirroring the selection bias with SI for well-preserved hepatic
function,most patients who received NT (78.1%) and ST (72.7%)
were Child–Pugh class B or C. For patients with advanced HCC,
cytotoxic systemic chemotherapy has failed to demonstrate an
overall survival benefit.54 A large randomized prospective trial
demonstrated that sorafenib, a targeted molecular therapy func-
tioning as a multikinase inhibitor, yielded a median survival of
10.7 months compared with 7.9 months for the placebo group.34,55
The overall risk of death was also decreased by 31%.34 A random-
ized Asia-Pacific study showed similar results.35 Subsequently,
guidelines currently recommend sorafenib as a first-line treat-
ment in patients with unresectable HCC who are not candidates
for TACE or ablative therapy.34,36 However, our study shows the
median survival of ST was only 2.8 months more than NT group,
which was not statistically significant (P = 0.309). This was most
probably because of a small sample size from an underestimation
of the ST group. Our analysis reports that less than 3% of patients
received systemic sorafenib. This underestimation results from
management of ST patients by their medical oncologists. As these
outpatient records were not recorded in the UPMC LCC registry,
all patients with ST were not captured – a limitation of our ret-
rospective study.
Randomized controlled trials and meta-analyses have exam-
ined arterial embolization (including bland embolization and
TACE) and demonstrated significant survival advantages com-
pared with conservative treatment.16,18,56–58 TACE has subse-
quently been included in treatment armamentarium for
HCC. Additionally, Y90 radioembolization has been used as
loco-regional therapy in patients with unresectable disease
and preserved liver function. Response rates of 39–47% have
been reported.46,59 A two-cohort study also demonstrated the
short-term outcomes of Y90 to be equivalent to TACE in well-
selected patients.21 In the present study, HAT was utilized for
63.3% of all patients. TACE and Y90 represented more than 70%
and less than 30% of HAT, respectively. Interestingly, 36.4% of
all SI patients also received HAT. While HAT was performed for
more than 20% of patients undergoing RFA and liver resection,
it was performed for more than 50% of patients receiving a
transplant.
Liver transplantation has the longest median survival (100.3
months) of all treatmentmodalities.At theUPMCLCC,all patients
with HCC were presented at a multidisciplinary tumour confer-
ence and were referred for liver transplant evaluation based on the
Milan criteria. Even after the initial implementation of the MELD
score for transplant allocation in 2002–2003, there are prolonged
waiting times as a result of organ shortage. Therefore, liver resec-
tion is still a frequent option for patients who recently became
transplant candidates. After subsequent addition of 22 bonus
points for patients with stage II HCC, there was a continued
increase in competition for donor organs, causing further growth
of waiting times. This lead to the increased use of minimally
invasive bridging therapy such as laparoscopic RFA. Multiple
bridging therapies to transplant were employed in an effort
to downstage the tumour to allow for listing and to delay
tumour progression to prevent dropouts while awaiting
transplantation.22–25,56 The American Association for the Study of
the Liver Diseases guidelines recommended the use of RFA and
TACE if the expected waiting time is longer than 6 months.60,61
However, there have been no randomized controlled trials to inves-
tigate different bridging treatmentmodalities for these patients.60,62
In the present study, the majority of patients who underwent liver
transplantation received prior therapy (75.4%) including HAT in
56.3%, RFA in 15.1% and liver resection in 4.0%. The median
survival for bridging to transplant with SI and HAT were 7.6 and
7.4months, respectively,whereas transplant alone was 6.1months;
however, this difference was not statistically significant (P = 0.111).
These outcomes of bridging therapy before transplant are consis-
tent with other published reports.22,24 The limitation of cadaveric
livers remains the most significant barrier in the management of
HCC, especially in Asia where the availability of organs is severely
limited. There is a great interest in living related liver transplanta-
tion to compensate for this limitation, and there is an ongoing
debate regarding expansionof theMilan criteria for thismodality.63
The majority of patients in this series had underlying cirrhosis
and viral hepatitis, predominately Child–Pugh class A (65.2% of
all cirrhotic patients) and HCV (30.7% of patients with recorded
hepatitis screening). Kaplan–Meier survival analysis demon-
strated survival advantages in patients with Child–Pugh class A
when compared with Child–Pugh class B or C. This is consistent
literature which demonstrated that Child–Pugh classification was
one of the most significant factors in predicting outcome.64 Inter-
estingly, there was no difference in survival between patients with
underlying HBV, HCV, and concomitant HBV and HCV.
However, in the context of survival after liver resection, HBV had
a statistically significant better survival compared with HCV (41.9
vs. 22.4 months, P < 0.05). Roayaie et al. also retrospectively com-
pared outcomes of liver resection for HCC in 43 HBV and 121
HCV patients.65 The 5-year disease-free survival was significantly
higher for HBV patients compared with HCV patients after liver
resection (49% vs. 7%, P = 0.048).65 This difference could be
because of poorer hepatic functional reserve and a greater asso-
ciation of cirrhosis with HCV.
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The role of AFP as a diagnostic and prognostic factor remains
controversial.66 AFP can be non-specifically elevated with cirrho-
sis, alcoholic liver disease and viral hepatitis.67 Therefore, the level
of AFP in patients with HCC can vary according to the aetiology
of underlying liver pathology. No broad consensus exists regard-
ing the use of AFP as a prognostic factor.66,67 However, the present
study demonstrates a significantly longer survival for patients
with an AFP < 400 ng/mL compared with patients with an AFP
400 ng/mL (20 vs. 5.8 months, P < 0.001). This significant survival
benefit was observed regardless of treatment modality. Univariate
analysis also implicates the prognostic value of AFP in patients
with HCC.
Themanagement of HCC has evolved significantly over the past
decade with evolving roles of loco-regional therapy and transplan-
tation in patients with HCC. Nevertheless, the only curative
options are liver resection and liver transplantation. Thus, it is of
great importance for community healthcare providers to work
closely with a tertiary care centre. A primary goal is public educa-
tion based on current evidence-based recommendations regarding
risk reduction, prevention, vaccination and screening protocols in
patients with a high risk for HCC. Once the patient is diagnosed
with HCC, timely referral to a tertiary care centre is essential.
The present study reports a large current series of HCC patients
evaluated at a Western Centre. While inherent treatment biases
limit the strength of conclusions that can be made, this retrospec-
tive study shows that proper patient selection can improve out-
comes by tailoring therapy to tumour pathology and hepatic
function. As we learn more about HCC molecular markers and
tumour biology, there is the potential for further optimization of
management. Future studies should address the promise of iden-
tifying the optimal therapeutic approaches based on a tumor’s
molecular biology.
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